Publicaciones en colaboración con investigadores/as de University of Michigan–Ann Arbor (64)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM

    Journal of Allergy and Clinical Immunology: In Practice

  4. Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease

    Nature Genetics, Vol. 56, Núm. 1, pp. 27-36

  5. The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study

    Diabetes, Obesity and Metabolism, Vol. 26, Núm. 3, pp. 950-960

2023

  1. Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  2. Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2) (npj Parkinson's Disease, (2023), 9, 1, (100), 10.1038/s41531-023-00526-9)

    npj Parkinson's Disease

  3. Cochlear synaptopathy impairs suprathreshold tone-in-noise coding in the cochlear nucleus

    Journal of Physiology, Vol. 601, Núm. 14, pp. 2991-3006

  4. Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

    npj Parkinson's Disease, Vol. 9, Núm. 1

  5. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  6. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020

2022

  1. A first update on mapping the human genetic architecture of COVID-19

    Nature

  2. Blood and Salivary Inflammatory Biomarkers Profile in Patients with Chronic Kidney Disease and Periodontal Disease: A Systematic Review

    Diseases, Vol. 10, Núm. 1

  3. Characteristics of a COVID-19 Cohort With Large Vessel Occlusion: A Multicenter International Study

    Neurosurgery, Vol. 90, Núm. 6, pp. 725-733

  4. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022

    Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 6, pp. 1855-1865

  5. Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 2, pp. 422-432

  6. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  7. International controlled study of revascularization and outcomes following COVID-positive mechanical thrombectomy

    European Journal of Neurology, Vol. 29, Núm. 11, pp. 3273-3287

  8. Olivocochlear projections contribute to superior intensity coding in cochlear nucleus small cells

    Journal of Physiology, Vol. 600, Núm. 1, pp. 61-73

  9. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6